Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 1 Pain (Visual Analogue Scale 10 cm).
Figuras y tablas -
Analysis 1.1

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 1 Pain (Visual Analogue Scale 10 cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 2 Pain (0‐12 scale).
Figuras y tablas -
Analysis 1.2

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 2 Pain (0‐12 scale).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 3 McGill Pain questionnaire.
Figuras y tablas -
Analysis 1.3

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 3 McGill Pain questionnaire.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 4 Ritchie Index.
Figuras y tablas -
Analysis 1.4

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 4 Ritchie Index.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 5 Health Assessment Questionnaire (HAQ).
Figuras y tablas -
Analysis 1.5

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 5 Health Assessment Questionnaire (HAQ).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 6 MCP ROM (degrees).
Figuras y tablas -
Analysis 1.6

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 6 MCP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 7 PIP ROM (degrees).
Figuras y tablas -
Analysis 1.7

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 7 PIP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 8 Knee ROM.
Figuras y tablas -
Analysis 1.8

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 8 Knee ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 9 Ankle ROM.
Figuras y tablas -
Analysis 1.9

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 9 Ankle ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 10 Flexibility‐ tip to palm distance (cm).
Figuras y tablas -
Analysis 1.10

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 10 Flexibility‐ tip to palm distance (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 11 Morning stiffness duration (min).
Figuras y tablas -
Analysis 1.11

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 11 Morning stiffness duration (min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 12 Morning stiffness not improved.
Figuras y tablas -
Analysis 1.12

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 12 Morning stiffness not improved.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 13 Rheumatoid factor positive.
Figuras y tablas -
Analysis 1.13

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 13 Rheumatoid factor positive.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 14 Grip strength.
Figuras y tablas -
Analysis 1.14

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 14 Grip strength.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 15 Suprapatellar swelling ‐ right knee (cm).
Figuras y tablas -
Analysis 1.15

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 15 Suprapatellar swelling ‐ right knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 16 Suprapatellar swelling‐ left knee (cm).
Figuras y tablas -
Analysis 1.16

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 16 Suprapatellar swelling‐ left knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 17 MCP swelling (cm).
Figuras y tablas -
Analysis 1.17

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 17 MCP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 18 PIP swelling (cm).
Figuras y tablas -
Analysis 1.18

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 18 PIP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 19 Walking speed (sec).
Figuras y tablas -
Analysis 1.19

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 19 Walking speed (sec).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 20 Fibrinogen.
Figuras y tablas -
Analysis 1.20

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 20 Fibrinogen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 21 Leukocytes.
Figuras y tablas -
Analysis 1.21

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 21 Leukocytes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 22 Lymphocytes.
Figuras y tablas -
Analysis 1.22

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 22 Lymphocytes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 23 ESR (mm/hr).
Figuras y tablas -
Analysis 1.23

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 23 ESR (mm/hr).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 24 CRP (g/mL).
Figuras y tablas -
Analysis 1.24

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 24 CRP (g/mL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 25 Hemoglobin.
Figuras y tablas -
Analysis 1.25

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 25 Hemoglobin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 26 Platelets.
Figuras y tablas -
Analysis 1.26

Comparison 1 Laser vs Placebo‐ End of treatment (approx 10 wks), Outcome 26 Platelets.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 1 Pain.
Figuras y tablas -
Analysis 2.1

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 1 Pain.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 2 McGill Pain questionnaire.
Figuras y tablas -
Analysis 2.2

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 2 McGill Pain questionnaire.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 3 Health Assessment Questionnaire (HAQ).
Figuras y tablas -
Analysis 2.3

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 3 Health Assessment Questionnaire (HAQ).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 4 Ritchie Index.
Figuras y tablas -
Analysis 2.4

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 4 Ritchie Index.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 5 PIP ROM (degrees).
Figuras y tablas -
Analysis 2.5

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 5 PIP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 6 Knee ROM.
Figuras y tablas -
Analysis 2.6

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 6 Knee ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 7 Ankle ROM.
Figuras y tablas -
Analysis 2.7

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 7 Ankle ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 8 MCP ROM (degrees).
Figuras y tablas -
Analysis 2.8

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 8 MCP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 9 Morning stiffness duration (min).
Figuras y tablas -
Analysis 2.9

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 9 Morning stiffness duration (min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 10 Walking speed (sec).
Figuras y tablas -
Analysis 2.10

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 10 Walking speed (sec).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 11 Grip strength.
Figuras y tablas -
Analysis 2.11

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 11 Grip strength.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 12 Suprapatellar swelling‐ left knee (cm).
Figuras y tablas -
Analysis 2.12

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 12 Suprapatellar swelling‐ left knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 13 Suprapatellar swelling ‐ right knee (cm).
Figuras y tablas -
Analysis 2.13

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 13 Suprapatellar swelling ‐ right knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 14 MCP swelling (cm).
Figuras y tablas -
Analysis 2.14

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 14 MCP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 15 PIP swelling (cm).
Figuras y tablas -
Analysis 2.15

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 15 PIP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 16 Thermographic index.
Figuras y tablas -
Analysis 2.16

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 16 Thermographic index.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 17 Rheumatoid factor positive.
Figuras y tablas -
Analysis 2.17

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 17 Rheumatoid factor positive.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 18 ESR (mm/hr).
Figuras y tablas -
Analysis 2.18

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 18 ESR (mm/hr).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 19 CRP (g/mL).
Figuras y tablas -
Analysis 2.19

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 19 CRP (g/mL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 20 Hemoglobin.
Figuras y tablas -
Analysis 2.20

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 20 Hemoglobin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 21 Platelets.
Figuras y tablas -
Analysis 2.21

Comparison 2 Laser vs Placebo‐ End of follow‐up (approx 20 wks), Outcome 21 Platelets.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Treatment length‐ subgroup analysis for end of treatment results, Outcome 1 Pain (10 cm VAS or 0‐12 scale).
Figuras y tablas -
Analysis 3.1

Comparison 3 Treatment length‐ subgroup analysis for end of treatment results, Outcome 1 Pain (10 cm VAS or 0‐12 scale).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Treatment length‐ subgroup analysis for end of follow up results, Outcome 1 Pain (10 cm VAS or 0‐12 scale).
Figuras y tablas -
Analysis 4.1

Comparison 4 Treatment length‐ subgroup analysis for end of follow up results, Outcome 1 Pain (10 cm VAS or 0‐12 scale).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Methodologic quality: low (<3) vs high (=> 3), Outcome 1 Pain at end of treatment.
Figuras y tablas -
Analysis 5.1

Comparison 5 Methodologic quality: low (<3) vs high (=> 3), Outcome 1 Pain at end of treatment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Laser vs Placebo ‐ Joint vs Nerve ‐ end of treatment, Outcome 1 Pain (10 cm VAS or 0‐12 scale).
Figuras y tablas -
Analysis 6.1

Comparison 6 Laser vs Placebo ‐ Joint vs Nerve ‐ end of treatment, Outcome 1 Pain (10 cm VAS or 0‐12 scale).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Laser vs Placebo ‐ Joint vs Nerve ‐ end of follow up, Outcome 1 Pain (10 cm VAS or 0‐12 scale).
Figuras y tablas -
Analysis 7.1

Comparison 7 Laser vs Placebo ‐ Joint vs Nerve ‐ end of follow up, Outcome 1 Pain (10 cm VAS or 0‐12 scale).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 1 Pain.
Figuras y tablas -
Analysis 8.1

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 1 Pain.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 2 McGill Pain questionnaire.
Figuras y tablas -
Analysis 8.2

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 2 McGill Pain questionnaire.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 3 Ritchie Index.
Figuras y tablas -
Analysis 8.3

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 3 Ritchie Index.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 4 Health Assessment Questionnaire (HAQ).
Figuras y tablas -
Analysis 8.4

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 4 Health Assessment Questionnaire (HAQ).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 5 MCP ROM (degrees).
Figuras y tablas -
Analysis 8.5

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 5 MCP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 6 PIP ROM (degrees).
Figuras y tablas -
Analysis 8.6

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 6 PIP ROM (degrees).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 7 Left knee Range of motion.
Figuras y tablas -
Analysis 8.7

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 7 Left knee Range of motion.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 8 Right knee ROM.
Figuras y tablas -
Analysis 8.8

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 8 Right knee ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 9 Left ankle ROM.
Figuras y tablas -
Analysis 8.9

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 9 Left ankle ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 10 Right ankle ROM.
Figuras y tablas -
Analysis 8.10

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 10 Right ankle ROM.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 11 Flexibility‐ tip to palm distance (cm).
Figuras y tablas -
Analysis 8.11

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 11 Flexibility‐ tip to palm distance (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 12 Morning stiffness duration (min).
Figuras y tablas -
Analysis 8.12

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 12 Morning stiffness duration (min).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 13 Morning stiffness not improved.
Figuras y tablas -
Analysis 8.13

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 13 Morning stiffness not improved.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 14 Rheumatoid factor positive.
Figuras y tablas -
Analysis 8.14

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 14 Rheumatoid factor positive.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 15 Grip strength (mmHg, KPa, kg).
Figuras y tablas -
Analysis 8.15

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 15 Grip strength (mmHg, KPa, kg).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 16 Suprapatellar swelling ‐ right knee (cm).
Figuras y tablas -
Analysis 8.16

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 16 Suprapatellar swelling ‐ right knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 17 Suprapatellar swelling‐ left knee (cm).
Figuras y tablas -
Analysis 8.17

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 17 Suprapatellar swelling‐ left knee (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 18 MCP swelling (cm).
Figuras y tablas -
Analysis 8.18

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 18 MCP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 19 PIP swelling (cm).
Figuras y tablas -
Analysis 8.19

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 19 PIP swelling (cm).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 20 Walking speed (sec).
Figuras y tablas -
Analysis 8.20

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 20 Walking speed (sec).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 21 Fibrinogen.
Figuras y tablas -
Analysis 8.21

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 21 Fibrinogen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 22 Leukocytes.
Figuras y tablas -
Analysis 8.22

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 22 Leukocytes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 23 Lymphocytes.
Figuras y tablas -
Analysis 8.23

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 23 Lymphocytes.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 24 ESR (mm/hr).
Figuras y tablas -
Analysis 8.24

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 24 ESR (mm/hr).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 25 CRP (g/mL).
Figuras y tablas -
Analysis 8.25

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 25 CRP (g/mL).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 26 Hemoglobin.
Figuras y tablas -
Analysis 8.26

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 26 Hemoglobin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 27 Platelets.
Figuras y tablas -
Analysis 8.27

Comparison 8 Laser vs Placebo‐ Wavelength analysis ‐ End of treatment, Outcome 27 Platelets.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 1 Pain VAS <= 3 J/cm2.
Figuras y tablas -
Analysis 9.1

Comparison 9 Subgroup Dosage Analysis, Outcome 1 Pain VAS <= 3 J/cm2.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 2 Pain VAS > 3 J/cm2.
Figuras y tablas -
Analysis 9.2

Comparison 9 Subgroup Dosage Analysis, Outcome 2 Pain VAS > 3 J/cm2.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 3 ESR low dose.
Figuras y tablas -
Analysis 9.3

Comparison 9 Subgroup Dosage Analysis, Outcome 3 ESR low dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 4 ESR high dose.
Figuras y tablas -
Analysis 9.4

Comparison 9 Subgroup Dosage Analysis, Outcome 4 ESR high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 5 CRP low dose.
Figuras y tablas -
Analysis 9.5

Comparison 9 Subgroup Dosage Analysis, Outcome 5 CRP low dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 6 CRP high dose.
Figuras y tablas -
Analysis 9.6

Comparison 9 Subgroup Dosage Analysis, Outcome 6 CRP high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 7 HAQ high dose.
Figuras y tablas -
Analysis 9.7

Comparison 9 Subgroup Dosage Analysis, Outcome 7 HAQ high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 8 Hemoglobin high dose.
Figuras y tablas -
Analysis 9.8

Comparison 9 Subgroup Dosage Analysis, Outcome 8 Hemoglobin high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 9 Morning stiffness (hours) high dose.
Figuras y tablas -
Analysis 9.9

Comparison 9 Subgroup Dosage Analysis, Outcome 9 Morning stiffness (hours) high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 10 Grip strength (kg) low.
Figuras y tablas -
Analysis 9.10

Comparison 9 Subgroup Dosage Analysis, Outcome 10 Grip strength (kg) low.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 11 Grip strength (kg) high.
Figuras y tablas -
Analysis 9.11

Comparison 9 Subgroup Dosage Analysis, Outcome 11 Grip strength (kg) high.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 12 MCP swelling (cm) low.
Figuras y tablas -
Analysis 9.12

Comparison 9 Subgroup Dosage Analysis, Outcome 12 MCP swelling (cm) low.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 13 Flexibility tip to palm (cm) low.
Figuras y tablas -
Analysis 9.13

Comparison 9 Subgroup Dosage Analysis, Outcome 13 Flexibility tip to palm (cm) low.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Subgroup Dosage Analysis, Outcome 14 Flexibility tip to palm high dose.
Figuras y tablas -
Analysis 9.14

Comparison 9 Subgroup Dosage Analysis, Outcome 14 Flexibility tip to palm high dose.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Laser vs Placebo‐ contralateral control (End of treatment), Outcome 1 Number of patients improved in pain relief.
Figuras y tablas -
Analysis 10.1

Comparison 10 Laser vs Placebo‐ contralateral control (End of treatment), Outcome 1 Number of patients improved in pain relief.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Laser vs Placebo‐ contralateral control (End of treatment), Outcome 2 Number of patients improved in morning stiffness.
Figuras y tablas -
Analysis 10.2

Comparison 10 Laser vs Placebo‐ contralateral control (End of treatment), Outcome 2 Number of patients improved in morning stiffness.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Laser vs Placebo‐ End of treatment (approx 10 wks)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain (Visual Analogue Scale 10 cm) Show forest plot

3

147

Mean Difference (IV, Fixed, 95% CI)

‐1.10 [‐1.82, ‐0.39]

2 Pain (0‐12 scale) Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

‐1.0 [‐1.77, ‐0.23]

3 McGill Pain questionnaire Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

1.5 [‐1.22, 4.22]

4 Ritchie Index Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

2.60 [‐4.50, 9.70]

5 Health Assessment Questionnaire (HAQ) Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

0.93 [‐2.01, 3.87]

6 MCP ROM (degrees) Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

‐0.5 [‐15.99, 14.99]

7 PIP ROM (degrees) Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

4.0 [‐6.60, 14.60]

8 Knee ROM Show forest plot

1

70

Mean Difference (IV, Fixed, 95% CI)

‐18.03 [‐31.80, ‐4.27]

8.1 Right knee ROM

1

35

Mean Difference (IV, Fixed, 95% CI)

‐12.90 [‐31.98, 6.18]

8.2 Left knee ROM

1

35

Mean Difference (IV, Fixed, 95% CI)

‐23.60 [‐43.47, ‐3.73]

9 Ankle ROM Show forest plot

1

70

Mean Difference (IV, Fixed, 95% CI)

4.60 [‐0.33, 9.53]

9.1 Right ankle ROM

1

35

Mean Difference (IV, Fixed, 95% CI)

5.90 [‐1.21, 13.01]

9.2 Left ankle ROM

1

35

Mean Difference (IV, Fixed, 95% CI)

3.40 [‐3.43, 10.23]

10 Flexibility‐ tip to palm distance (cm) Show forest plot

2

57

Mean Difference (IV, Fixed, 95% CI)

‐1.28 [‐1.72, ‐0.85]

11 Morning stiffness duration (min) Show forest plot

3

110

Mean Difference (IV, Fixed, 95% CI)

‐27.45 [‐51.95, ‐2.95]

12 Morning stiffness not improved Show forest plot

1

22

Risk Ratio (M‐H, Fixed, 95% CI)

0.76 [0.49, 1.19]

13 Rheumatoid factor positive Show forest plot

1

35

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.61, 1.34]

14 Grip strength Show forest plot

3

97

Mean Difference (IV, Fixed, 95% CI)

0.62 [‐0.36, 1.60]

14.1 Grip strength (mmHg)

2

75

Mean Difference (IV, Fixed, 95% CI)

7.71 [0.15, 15.27]

14.2 Grip strength (kg)

1

22

Mean Difference (IV, Fixed, 95% CI)

0.5 [‐0.49, 1.49]

15 Suprapatellar swelling ‐ right knee (cm) Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

‐2.94 [‐6.31, 0.43]

16 Suprapatellar swelling‐ left knee (cm) Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

‐2.69 [‐6.33, 0.95]

17 MCP swelling (cm) Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐0.78, 1.18]

18 PIP swelling (cm) Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

0.53 [‐1.12, 2.18]

19 Walking speed (sec) Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

‐1.87 [‐7.08, 3.34]

20 Fibrinogen Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

1.5 [‐0.00, 3.00]

21 Leukocytes Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

1.60 [0.62, 2.58]

22 Lymphocytes Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

3.0 [‐6.57, 12.57]

23 ESR (mm/hr) Show forest plot

3

92

Mean Difference (IV, Fixed, 95% CI)

‐10.09 [‐15.04, ‐5.15]

24 CRP (g/mL) Show forest plot

2

57

Mean Difference (IV, Fixed, 95% CI)

2.55 [‐14.11, 19.21]

25 Hemoglobin Show forest plot

2

70

Mean Difference (IV, Fixed, 95% CI)

0.47 [0.01, 0.93]

26 Platelets Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

20.35 [‐64.36, 105.06]
Figuras y tablas -
Comparison 1. Laser vs Placebo‐ End of treatment (approx 10 wks)
Ir a la tabla de la revisión
Comparison 2. Laser vs Placebo‐ End of follow‐up (approx 20 wks)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

0.06 [‐1.24, 1.36]

1.1 Pain (10 cm visual analogue scale)

2

54

Mean Difference (IV, Fixed, 95% CI)

0.06 [‐1.24, 1.36]

2 McGill Pain questionnaire Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

1.39 [‐2.23, 5.01]

3 Health Assessment Questionnaire (HAQ) Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

1.10 [‐2.80, 4.99]

4 Ritchie Index Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

3.30 [‐5.74, 12.34]

5 PIP ROM (degrees) Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

2.0 [‐16.30, 20.30]

6 Knee ROM Show forest plot

1

56

Mean Difference (IV, Fixed, 95% CI)

‐11.47 [‐31.26, 8.31]

6.1 Right knee ROM

1

28

Mean Difference (IV, Fixed, 95% CI)

‐13.60 [‐41.44, 14.24]

6.2 Left knee ROM

1

28

Mean Difference (IV, Fixed, 95% CI)

‐9.30 [‐37.43, 18.83]

7 Ankle ROM Show forest plot

1

56

Mean Difference (IV, Fixed, 95% CI)

‐1.20 [‐11.69, 9.28]

7.1 Right ankle ROM

1

28

Mean Difference (IV, Fixed, 95% CI)

1.80 [‐12.59, 16.19]

7.2 Left ankle ROM

1

28

Mean Difference (IV, Fixed, 95% CI)

‐4.60 [‐19.91, 10.71]

8 MCP ROM (degrees) Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

10.0 [‐6.86, 26.86]

9 Morning stiffness duration (min) Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

12.16 [‐31.00, 55.31]

10 Walking speed (sec) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐1.91 [‐12.60, 8.78]

11 Grip strength Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

‐29.0 [‐61.44, 3.44]

11.1 Grip strength (mmHg)

1

26

Mean Difference (IV, Fixed, 95% CI)

‐29.0 [‐61.44, 3.44]

11.2 Grip strength (kg)

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Suprapatellar swelling‐ left knee (cm) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐2.89 [‐14.38, 8.60]

13 Suprapatellar swelling ‐ right knee (cm) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐3.29 [‐14.66, 8.08]

14 MCP swelling (cm) Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

‐0.40 [‐1.23, 0.43]

15 PIP swelling (cm) Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

0.90 [‐1.88, 3.68]

16 Thermographic index Show forest plot

1

26

Mean Difference (IV, Fixed, 95% CI)

0.60 [‐0.11, 1.31]

17 Rheumatoid factor positive Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.60, 1.68]

18 ESR (mm/hr) Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐26.94, 22.94]

19 CRP (g/mL) Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

‐4.21 [‐20.25, 11.83]

20 Hemoglobin Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

0.98 [‐0.21, 2.16]

21 Platelets Show forest plot

2

54

Mean Difference (IV, Fixed, 95% CI)

32.68 [‐37.76, 103.11]
Figuras y tablas -
Comparison 2. Laser vs Placebo‐ End of follow‐up (approx 20 wks)
Ir a la tabla de la revisión
Comparison 3. Treatment length‐ subgroup analysis for end of treatment results

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain (10 cm VAS or 0‐12 scale) Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Treatment for 4 weeks

3

97

Mean Difference (IV, Fixed, 95% CI)

‐0.83 [‐1.46, ‐0.20]

1.2 Treatment for 10 weeks

1

72

Mean Difference (IV, Fixed, 95% CI)

‐1.54 [‐2.47, ‐0.61]
Figuras y tablas -
Comparison 3. Treatment length‐ subgroup analysis for end of treatment results
Ir a la tabla de la revisión
Comparison 4. Treatment length‐ subgroup analysis for end of follow up results

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain (10 cm VAS or 0‐12 scale) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Treatment for 4 weeks

2

54

Mean Difference (IV, Fixed, 95% CI)

0.06 [‐1.24, 1.36]

1.2 Treatment for 10 weeks

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 4. Treatment length‐ subgroup analysis for end of follow up results
Ir a la tabla de la revisión
Comparison 5. Methodologic quality: low (<3) vs high (=> 3)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain at end of treatment Show forest plot

4

169

Mean Difference (IV, Fixed, 95% CI)

‐1.05 [‐1.58, ‐0.53]

1.1 Low quality (<3)

2

107

Mean Difference (IV, Fixed, 95% CI)

‐1.39 [‐2.23, ‐0.56]

1.2 High quality (=> 3)

2

62

Mean Difference (IV, Fixed, 95% CI)

‐0.84 [‐1.51, ‐0.16]
Figuras y tablas -
Comparison 5. Methodologic quality: low (<3) vs high (=> 3)
Ir a la tabla de la revisión
Comparison 6. Laser vs Placebo ‐ Joint vs Nerve ‐ end of treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain (10 cm VAS or 0‐12 scale) Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Joint application

3

97

Mean Difference (IV, Fixed, 95% CI)

‐0.83 [‐1.46, ‐0.20]

1.2 Nerve application

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Joint and nerve application

1

72

Mean Difference (IV, Fixed, 95% CI)

‐1.54 [‐2.47, ‐0.61]
Figuras y tablas -
Comparison 6. Laser vs Placebo ‐ Joint vs Nerve ‐ end of treatment
Ir a la tabla de la revisión
Comparison 7. Laser vs Placebo ‐ Joint vs Nerve ‐ end of follow up

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain (10 cm VAS or 0‐12 scale) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Joint application

2

54

Mean Difference (IV, Fixed, 95% CI)

0.06 [‐1.24, 1.36]

1.2 Nerve application

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 Joint and nerve application

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 7. Laser vs Placebo ‐ Joint vs Nerve ‐ end of follow up
Ir a la tabla de la revisión
Comparison 8. Laser vs Placebo‐ Wavelength analysis ‐ End of treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 Wavelength < 660 nm

1

72

Mean Difference (IV, Fixed, 95% CI)

‐1.54 [‐2.47, ‐0.61]

1.2 Wavelength 820, 830 nm

2

62

Mean Difference (IV, Fixed, 95% CI)

‐0.84 [‐1.51, ‐0.16]

1.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐0.78 [‐2.68, 1.12]

2 McGill Pain questionnaire Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

1.5 [‐1.22, 4.22]

3 Ritchie Index Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

3.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Wavelength 820, 830 nm

1

40

Mean Difference (IV, Fixed, 95% CI)

2.60 [‐4.50, 9.70]

3.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Health Assessment Questionnaire (HAQ) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

4.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Wavelength 820, 830 nm

1

40

Mean Difference (IV, Fixed, 95% CI)

1.25 [‐2.09, 4.59]

4.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐0.18 [‐6.39, 6.03]

5 MCP ROM (degrees) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

5.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Wavelength 820, 830 nm

1

40

Mean Difference (IV, Fixed, 95% CI)

‐0.5 [‐15.99, 14.99]

5.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 PIP ROM (degrees) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

6.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Wavelength 820, 830 nm

1

40

Mean Difference (IV, Fixed, 95% CI)

4.0 [‐6.60, 14.60]

6.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Left knee Range of motion Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

7.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐23.60 [‐43.47, ‐3.73]

8 Right knee ROM Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

8.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐12.90 [‐31.98, 6.18]

9 Left ankle ROM Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

9.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

3.40 [‐3.43, 10.23]

10 Right ankle ROM Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

10.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

7.90 [0.79, 15.01]

11 Flexibility‐ tip to palm distance (cm) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

11.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 Wavelength 820, 830 nm

2

57

Mean Difference (IV, Fixed, 95% CI)

‐1.28 [‐1.72, ‐0.85]

11.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Morning stiffness duration (min) Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

12.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12.2 Wavelength 820, 830 nm

2

75

Mean Difference (IV, Fixed, 95% CI)

‐30.65 [‐55.71, ‐5.58]

12.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

40.80 [‐75.05, 156.65]

13 Morning stiffness not improved Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

13.1 Wavelength < 660 nm

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

13.2 Wavelength 820, 830 nm

1

22

Risk Ratio (M‐H, Fixed, 95% CI)

0.76 [0.49, 1.19]

13.3 Wavelength 650‐950 nm

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

14 Rheumatoid factor positive Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 Wavelength < 660 nm

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.2 Wavelength 820, 830 nm

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

14.3 Wavelength 650‐950 nm

1

35

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.61, 1.34]

15 Grip strength (mmHg, KPa, kg) Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

15.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15.2 Wavelength 820, 830 nm

3

97

Mean Difference (IV, Fixed, 95% CI)

0.62 [‐0.36, 1.60]

15.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16 Suprapatellar swelling ‐ right knee (cm) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

16.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

16.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐2.94 [‐6.31, 0.43]

17 Suprapatellar swelling‐ left knee (cm) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

17.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

17.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐2.69 [‐6.33, 0.95]

18 MCP swelling (cm) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

18.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

18.2 Wavelength 820, 830 nm

1

40

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐0.78, 1.18]

18.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

19 PIP swelling (cm) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

19.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

19.2 Wavelength 820, 830 nm

2

75

Mean Difference (IV, Fixed, 95% CI)

0.53 [‐1.12, 2.18]

19.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20 Walking speed (sec) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

20.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

20.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐1.87 [‐7.08, 3.34]

21 Fibrinogen Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

21.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

21.2 Wavelength 820, 830 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

1.5 [‐0.00, 3.00]

21.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22 Leukocytes Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

22.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

22.2 Wavelength 820, 830 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

1.60 [0.62, 2.58]

22.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23 Lymphocytes Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

23.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

23.2 Wavelength 820, 830 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

3.0 [‐6.57, 12.57]

23.3 Wavelength 650‐950 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24 ESR (mm/hr) Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

24.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

24.2 Wavelength 820, 830 nm

2

57

Mean Difference (IV, Fixed, 95% CI)

‐11.12 [‐16.21, ‐6.04]

24.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

8.27 [‐13.18, 29.72]

25 CRP (g/mL) Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

25.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

25.2 Wavelength 820, 830 nm

1

22

Mean Difference (IV, Fixed, 95% CI)

‐120.0 [‐190.13, ‐49.87]

25.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

9.88 [‐7.27, 27.03]

26 Hemoglobin Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

26.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

26.2 Wavelength 820, 830 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

0.60 [0.11, 1.09]

26.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

‐0.69 [‐2.12, 0.74]

27 Platelets Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

27.1 Wavelength < 660 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

27.2 Wavelength 820, 830 nm

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

27.3 Wavelength 650‐950 nm

1

35

Mean Difference (IV, Fixed, 95% CI)

20.35 [‐64.36, 105.06]
Figuras y tablas -
Comparison 8. Laser vs Placebo‐ Wavelength analysis ‐ End of treatment
Ir a la tabla de la revisión
Comparison 9. Subgroup Dosage Analysis

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Pain VAS <= 3 J/cm2 Show forest plot

2

94

Mean Difference (IV, Fixed, 95% CI)

‐1.22 [‐1.81, ‐0.63]

2 Pain VAS > 3 J/cm2 Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

‐0.47 [‐1.59, 0.65]

3 ESR low dose Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

‐20.0 [‐28.69, ‐11.31]

4 ESR high dose Show forest plot

2

70

Mean Difference (IV, Fixed, 95% CI)

‐5.34 [‐11.35, 0.68]

5 CRP low dose Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

‐120.0 [‐190.13, ‐49.87]

6 CRP high dose Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

9.88 [‐7.27, 27.03]

7 HAQ high dose Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

0.93 [‐2.01, 3.87]

8 Hemoglobin high dose Show forest plot

2

70

Mean Difference (IV, Fixed, 95% CI)

0.47 [0.01, 0.93]

9 Morning stiffness (hours) high dose Show forest plot

3

110

Mean Difference (IV, Fixed, 95% CI)

‐27.45 [‐51.95, ‐2.95]

10 Grip strength (kg) low Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

0.5 [‐0.49, 1.49]

11 Grip strength (kg) high Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

7.71 [0.15, 15.27]

12 MCP swelling (cm) low Show forest plot

2

75

Mean Difference (IV, Fixed, 95% CI)

0.53 [‐1.12, 2.18]

13 Flexibility tip to palm (cm) low Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

‐1.25 [‐1.68, ‐0.82]

14 Flexibility tip to palm high dose Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

‐6.0 [‐11.25, ‐0.75]
Figuras y tablas -
Comparison 9. Subgroup Dosage Analysis
Ir a la tabla de la revisión
Comparison 10. Laser vs Placebo‐ contralateral control (End of treatment)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of patients improved in pain relief Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

13.0 [0.79, 214.05]

2 Number of patients improved in morning stiffness Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

4.0 [0.50, 32.20]
Figuras y tablas -
Comparison 10. Laser vs Placebo‐ contralateral control (End of treatment)
Ir a la tabla de la revisión